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 11  -Hydroxysteroid dehydrogenase type 1 (11  -HSD1) 
is a NADPH-dependent enzyme catalyzing the regener-
ation of cortisol (in humans, higher mammals) and cor-
ticosterone (in rodents) from inactive cortisone and 
11-dehydrocorticosterone, respectively, thereby controlling 
the tissue- and cell-specifi c exposure to active glucocorti-
coids ( 1 ). Locally increased glucocorticoid levels, espe-
cially in adipose tissue, have been implicated in the 
pathogenesis of the metabolic syndrome, characterized 
by glucose intolerance, insulin resistance, dyslipidemia, 
and hypertension ( 2, 3 ). Evidence from experiments 
with transgenic mice (knockout or overexpression of 
11  -HSD1) and selective inhibitors revealed benefi cial 
effects of 11  -HSD1 inhibition on almost all major pa-
rameters of the metabolic syndrome ( 4–13 ). Data from 
human phase II clinical trials supported the results ob-
tained from animal studies ( 14, 15 ). Currently, several 
pharmaceutical companies are developing selective 11  -
HSD1 inhibitors for treatment of metabolic diseases, 
osteoporosis, age-associated cognitive defi ciencies, and 
wound healing ( 15–17 ). 
 Suitable biomarkers to detect impaired 11  -HSD1 func-
tion in vivo and monitor inhibition of 11  -HSD1 in pre-
clinical and clinical studies are still not available, and there 
is a great interest to identify such biomarkers for diagnostic 
purposes and to assess the effi cacy of therapeutic inhibitors. 
 Abstract  11  -hydroxysteroid dehydrogenase type 1 (11  -
HSD1) mediates glucocorticoid activation and is currently 
considered as therapeutic target to treat metabolic diseases; 
however, biomarkers to assess its activity in vivo are still 
lacking. Recent in vitro experiments suggested that human 
11  -HSD1 metabolizes the secondary bile acid 7-oxolitho-
cholic acid (7-oxoLCA) to chenodeoxycholic acid (CDCA) 
and minor amounts of ursodeoxycholic acid (UDCA). Here, 
we provide evidence from in vitro and in vivo studies for a 
major role of 11  -HSD1 in the oxidoreduction of 7-oxoLCA 
and compare its level and metabolism in several species. 
Hepatic microsomes from liver-specifi c 11  -HSD1-defi cient 
mice were devoid of 7-oxoLCA oxidoreductase activity. Im-
portantly, circulating and intrahepatic levels of 7-oxoLCA 
and its taurine conjugate were signifi cantly elevated in 
mouse models of 11  -HSD1 defi ciency. Moreover, compar-
ative enzymology of 11  -HSD1-dependent oxidoreduction 
of 7-oxoLCA revealed that the guinea-pig enzyme is devoid 
of 7-oxoLCA oxidoreductase activity. Unlike in other species, 
7-oxoLCA and its glycine conjugate are major bile acids in 
guinea-pigs.  In conclusion, the oxidoreduction of 7-oxoLCA 
and its conjugated metabolites are catalyzed by 11  -HSD1, 
and the lack of this activity leads to the accumulation of these 
bile acids in guinea-pigs and 11  -HSD1-defi cient mice. Thus, 
7-oxoLCA and its conjugates may serve as biomarkers of 
impaired 11  -HSD1 activity. —Penno, C. A., S. A. Morgan, 
A. Vuorinen, D. Schuster, G. G. Lavery, and A. Odermatt. 
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 Reduction of 7-oxoLCA by recombinant 11  -HSD1 from 
various species 
 To assess species-dependent differences in the 11  -HSD1-
dependent metabolism of 7-oxoLCA, we transiently transfected 
HEK-293 (human embryonic kidney-293) cells [cultured in 
Dulbecco’s Modifi ed Eagle’s Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 50 units/ml penicillin, 
50   g/ml streptomycin and 2 mM glutamine] with plasmids 
coding for human, rat, mouse, hamster, canine, and guinea-pig 
11  -HSD1 as described previously ( 23, 29, 30 ). At 48 h post-
transfection (jetPRIME, Polyplus transfection, Illkirch, France) 
cells were detached and centrifuged, and pellets were stored at 
  80°C. Cell pellets were resuspended in TS2 buffer (100 mM 
NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl 2 , 250 mM sucrose, 
and 20 mM Tris/HCl, pH 7.4), sonicated, and used immediately 
to measure enzyme activity. 
 To determine apparent K m and V max values, lysates were incu-
bated for 10 min at 37°C in a total volume of 20   l containing 
500   M NADPH and 7-oxoLCA at concentrations between 
62.5 nM and 4   M. To determine the relative content of product 
formed, lysates at a high total protein concentration (to achieve 
almost complete substrate conversion) were incubated with 1 µM 
of 7-oxoLCA for 10 min. Reactions were terminated by adding 
80 µl of acetonitrile containing 100 nM of CDCA-d4. Concomi-
tantly, lysates were used in parallel experiments to assess the con-
version of cortisone to cortisol. Reaction products were directly 
measured by mass spectrometry as described previously ( 26, 31 ). 
The rate of all reactions was kept below 25% of substrate conver-
sion, with the exception of the comparison of product formation 
from 7-oxoLCA shown in  Fig. 1A . 
 The expression of recombinant C-terminally FLAG-tagged 
11  -HSD1 in different transfection experiments was determined 
semiquantitatively by immunoblotting. Protein concentrations 
were determined by the bicinchoninic acid (BCA) method. An 
amount of 25 µg of total protein was resolved on 12% Bis-Tris gels 
(NuPage®, Invitrogen) using 1X MES as buffer (Invitrogen, 
NuPAGE® MES SDS Running Buffer) and then transferred to ni-
trocellulose membranes (iBlot®, Invitrogen). Thereafter, mem-
branes were blocked with Odyssey® blocking buffer (LI-COR, Bio-
sciences, Lincoln, NE) overnight at 4°C. Immunoreactions were 
carried out with primary anti-FLAG antibody M2 (Invitrogen) to 
detect the recombinant enzyme and with secondary goat anti-
mouse Alexa Fluor® 790 antibody, respectively (Invitrogen). After 
immunoreaction of FLAG-tagged enzymes, the membranes were 
stripped and incubated with an antibody against   -actin (Sigma). 
All detection and quantifi cation reactions were performed using a 
LI-COR Odyssey infrared imaging system (LI-COR, Biosciences, 
Lincoln, NE). 
 Impact of bile acids on the interconversion of 
glucocorticoids by 11  -HSD1 of six species 
 The inhibitory impact of bile acids on the interconversion of 
glucocorticoids by 11  -HSD1 of six species was performed as de-
scribed previously ( 26 ). Briefl y, lysates were incubated for 10 min 
at 37°C in a total volume of 22   l containing 200 nM and 10 nCi 
of [1,2- 3 H]cortisone or [1,2,6,7- 3 H]cortisol and 500   M cofactor 
NADPH or NADP + , respectively, and vehicle or various concen-
trations of bile acids. Following the interconversion of radiola-
beled glucocorticoids and termination of reactions by adding 
methanol containing 2 mM of unlabeled cortisone and cortisol, 
15   l were spotted on Polygram SIL G-25 UV254 silica plates 
(Macherey-Nagel, Oensingen, Switzerland). Plates were dried, 
and cortisone and cortisol were resolved using a solvent system of 
9:1 (v/v) chloroform/methanol. The separated steroids were 
analyzed by scintillation counting. 
Circulating concentrations of glucocorticoids and their 
metabolites are not suitable biomarkers because their 
levels in plasma and urine are a result of combined ac-
tivities of 11  -HSD1 and 11  -HSD2. Furthermore, an 
ideal biomarker should be independent of mechanisms 
of negative feedback regulation, such as the control of 
circulating glucocorticoid levels by the hypothalamus-
pituitary-adrenal (HPA) axis and stress-induced fl uctua-
tions ( 18, 19 ). 
 11  -HSD1 has broad substrate specifi city and metabo-
lizes, besides 11-ketoglucocorticoids, several oxidized en-
dogenous steroids and sterols ( 19–25 ). Performing in vitro 
experiments, we recently identifi ed a novel role for hu-
man 11  -HSD1 in the metabolism of the secondary bile 
acid 7-oxoLCA ( 26 ). We observed that recombinant hu-
man 11  -HSD1 preferentially reduced 7-oxoLCA to the 
7  -hydroxylated bile acid chenodeoxycholic acid (CDCA) 
and, to a lesser extent, to the 7  -hydroxylated ursodeoxy-
cholic acid (UDCA) ( 26 ). We hypothesized that the me-
tabolism by 11  -HSD1 might be responsible for the very 
low circulating levels of this secondary bile acid. 7-oxoLCA 
is formed from CDCA and UDCA in the colon by 7  -
hydroxysteroid dehydrogenases from microorganisms 
such as  Escherichia coli , Bacteroides fragilis , and  Bacteroides in-
testinalis ( 27, 28 ). Thereafter, 7-oxoLCA is reabsorbed in 
the intestine and reaches the liver through the enterohe-
patic cycle. 
 In the present study, we aimed to  i ) obtain further in 
vitro and in vivo evidence for a role of 11  -HSD1 in the oxi-
doreduction of 7-oxoLCA,  ii ) assess species-specifi c dif-
ferences in the 11  -HSD1-dependent oxidoreduction of 
7-oxoLCA, and  iii ) test our hypothesis that 7-oxoLCA might 
accumulate in transgenic 11  -HSD1-defi cient mice and pro-
vide initial evidence that this bile acid might serve as a bio-
marker for 11  -HSD1 defi ciency. 
 MATERIALS AND METHODS 
 Chemicals and reagents 
 CDCA, UDCA, [2,2,4,4- 2 H 4 ]CDCA (CDCA-d4) (>98% isotopic 
purity), and [9,11,12,12- 2 H 4 ]cortisol (cortisol-d4) (>98% isotopic 
purity) were purchased from Sigma-Aldrich (St. Louis, MO). 
7-oxolithocholic acid (7-oxoLCA) was purchased from Steraloids 
(Newport, RI). 7-oxolithocholyltaurine (7-oxoLC-Tau) and 7-oxo-
lithocholylglycine (7-oxoLC-Gly) were a kind gift from Dr. Alan F. 
Hofmann (University of California, San Diego, CA). Cell culture 
media were purchased from Invitrogen (Carlsbad, CA) and Sigma 
(Buchs, Switzerland). [1,2- 3 H]cortisone was obtained from Ameri-
can Radiolabeled Chemicals (St. Louis, MO), [1,2,6,7- 3 H]cortisol 
from Amersham Pharmacia (Piscataway, NJ), and tricyclo[3.3.1.13,7]
dec-1-yl-6,7,8,9-tetrahydro-5H-1,2,4-triazolo[4,3-a]azepine (T0504) 
from Enamine (Kiev, Ukraine). The construction of expression 
plasmids has been described earlier ( 29, 30 ). Male human and 
guinea-pig liver microsomes were obtained from Celsis Interna-
tional Ltd. (Brussels, Belgium), and serum samples from 12–16 h 
fasted adult male mice (balb/c and C57bL/6), rats (Han Wistar 
and Sprague-Dawley), dog ( Canis familiaris , beagle bred), guinea-
pigs (Dunkin-Hartley), and hamsters (golden Syrian) were ob-
tained from Harlan (Gannat, France). 
 by guest, on Novem
ber 21, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2013/08/09/jlr.M042499.DC1
Supplemental Material can be found at:
2876 Journal of Lipid Research Volume 54, 2013
Committee of the University of Birmingham (Birmingham, 
United Kingdom) in accordance with the UK Animals (Scientifi c 
Procedures) Act, 1986. Mice were kept in a climate-controlled 
facility, housed under standard conditions on a 12 h light/dark 
cycle, and fed ad libitum with standard chow and free access to 
drinking water. 
 To assess the impact of 11  -HSD1 on the circulating and intra-
hepatic levels of 7-oxoLCA and its conjugated metabolites, 15-
week-old wild-type mice (n = 16), 11  -HSD1 global KO (n = 8), 
and 11  -HSD1 liver-specifi c KO (n = 16), previously described in 
Ref.  33 , were fasted overnight, and blood samples were collected 
by intracardiac puncture. Plasma was prepared immediately by 
centrifugation, and samples were stored at   80°C until further 
processing. 
 Quantifi cation of 7-oxoLCA and its taurine and glycine 
conjugates by LC-MS/MS 
 Extraction and quantifi cation of bile acids in plasma samples 
was performed essentially as described previously ( 31 ). The ex-
traction of bile acids from liver tissue was performed by homog-
enizing 100 mg of tissue in 200 µl 50% methanol. Samples were 
spiked with 300 µl of deuterium labeled bile acids as internal 
standards (CDCA-d4) at a fi nal concentration of 1 µM in ace-
tonitrile, followed by protein precipitation by adding 1.5 ml of 
alkaline (5% NH 4 OH) ice-cold acetonitrile. Thereafter, samples 
were mixed continuously for 1 h and centrifuged at 11,000  g for 
10 min. The supernatant was transferred to a new tube, the sol-
vent was evaporated, and the residue was reconstituted in 100 µl 
of 50% methanol, followed by an additional centrifugation step 
to remove insoluble particles. The method was qualifi ed on the 
basis of extraction effi ciency, intraday accuracy, and precision for 
7-oxoLCA, 7-oxoLC-Tau, and 7-oxoLC-Gly (data not shown). The 
method presented acceptable extraction effi ciency, accuracy, and 
precision for the bile acids studied. 
 Calculation of enzyme kinetic parameters 
 Enzyme kinetics was analyzed by nonlinear regression using 
four-parameter logistic curve fi tting. For statistical comparisons, 
the ratio  t -test in GraphPad Prism 5 software was used. Results 
(mean ± SD) were obtained from at least three independent ex-
periments. For calculation of V max , the expression level of the 
FLAG-tagged enzyme was normalized to the expression signal of 
the internal control   -actin. 
 Microsomal preparations and activity assays with 
hepatic microsomes 
 Microsomes from livers of wild-type and liver-specifi c 11  -
HSD1-knockout mice were prepared as described earlier ( 32 ). 
The quality of microsomal preparations was validated by using a 
kit to measure cytochrome c reductase activity (Sigma, Saint Louis, 
MO). 11  -HSD1 reductase activity was determined by incubation 
of microsomes (0.05 mg/ml) for 60 min at 37°C in a total volume 
of 25   l containing TS2 buffer, 500   M NADPH or 1 mM glu-
cose-6-phosphate (G6P), 1   M 7-oxoLCA or 1 µM cortisone, and 
vehicle or 5   M of the 11  -HSD1 inhibitor T0504 as indicated. 
Substrates and inhibitors were diluted from 10 mM stock solu-
tions in DMSO or methanol. The fi nal solvent concentration in 
all reactions was kept below 0.2%. Reactions were started by 
adding microsomes into freshly prepared reaction mixture and 
stopped by adding 500 µl of acetonitrile containing CDCA-d4 
and cortisol-d4 at a concentration of 100 nM as internal stan-
dards for LC-MS/MS analysis. Thereafter, the organic phase was 
evaporated to dryness, and samples were reconstituted in 50% 
methanol/water solution, followed by injection into the LC-MS/
MS instrument. 
 Animal experimentation 
 Animal studies were conducted under Home Offi ce license and 
following approval of the Joint Ethics and Research Governance 
 Fig.  1. Enzymatic activity of recombinant 11  -HSD1 from various species was determined in lysates of 
transfected HEK-293 cells as described in Materials and Methods. (A) Stereoselective oxidoreduction of 
7-oxoLCA (1 µM) to CDCA (black bars) and UDCA (white bars) by 11  -HSD1 from various species after 
incubation for 10 min at 37°C. (B) Guinea-pig liver microsomes were incubated for 40 min with 7-oxoLCA 
(1   M) and glucose-6-phosphate (1 mM). Bile acids were extracted and quantitated by LC-MS/MS. Uncon-
verted 7-oxoLCA is represented by black bars. Data (n = 3) represent mean ± SD. (C) Oxidoreduction of 
cortisone by guinea-pig liver microsomes. (D) Western blotting against 11  -HSD1 in guinea-pig (GPLm) and 
mouse liver microsomes (MLm). 
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for 10 min to convert most of the substrate and to assess 
the relative composition of products formed. Human 11  -
HSD1 preferentially formed CDCA with minor amounts of 
UDCA as reported earlier ( 26 ). Canine and hamster 11  -
HSD1 almost completely converted the substrate and pre-
sented similar stereoselectivity to human 11  -HSD1, thus 
mainly producing the 7  -hydroxylated bile acid CDCA, 
with minor amounts of the 7  -hydroxylated UDCA. Rat 
and mouse 11  -HSD1 also almost completely converted 
the substrate and reduced 7-oxoLCA to signifi cant amounts 
of both CDCA and UDCA ( Fig. 1A ). Surprisingly, we could 
detect only background activity of 7-oxoLCA oxidoreduc-
tion when using HEK-293 cell lysates expressing recombi-
nant guinea-pig 11  -HSD1 or when using guinea-pig liver 
microsomes ( Fig. 1A, B ). Under the same conditions, cor-
tisone was effi ciently reduced by recombinant guinea-pig 
11  -HSD1 ( Fig. 1C ,  Table 1 ),  with an activity at 4 µM cor-
tisone that was about two times higher than that of the 
human enzyme, in line with an earlier report on kinetic 
parameters for glucocorticoids as substrates of 11  -HSD1 
( 29 ). On the other hand, 11  -HSD1 from human, mouse, 
rat, hamster, and dog efficiently converted 7-oxoLCA 
( Table 1 ) with K m values ranging 1.2–5.0 µM and V max val-
ues ranging 24–107 nmol × mg   1 × h   1 . None of the 11  -
HSD1 enzymes was able to catalyze the conversion of either 
CDCA or UDCA to 7-oxoLCA at pH 7.4 and in the pres-
ence of NADP + , suggesting that exclusively the reduction 
is catalyzed under physiological conditions. 
 Inhibition of the 11  -HSD1-dependent interconversion 
of glucocorticoids by bile acids 
 Next, we investigated whether 7-oxoLCA, CDCA, or 
UDCA can inhibit 11  -HSD1 reductase and dehydroge-
nase activity, respectively, and assessed species-specific 
differences. A preferential inhibition of the reductase 
reaction was observed when using 7-oxoLCA, except for 
the guinea-pig enzyme, which showed weak inhibition with 
all three bile acids analyzed, independent of whether re-
duction or oxidation was measured ( Table 2 ).  The IC 50 
values obtained for both reductase and dehydrogenase 
activity did not refl ect the ability of a given bile acid to 
serve as a substrate/product. Human and hamster 11  -HSD1 
showed lowest IC 50 values for 7-oxoLCA on cortisone re-
duction, while rat, mouse, and canine 11  -HSD1 reductase 
activity was equally well inhibited by 7-oxoLCA and CDCA 
and less efficiently by UDCA. Interestingly, although 
CDCA potently inhibited cortisone reduction by 11  -HSD1, 
 Statistical analysis 
 Data are presented as mean ± SD. Statistical signifi cance was 
assessed by Student  t -test.  P   0.05 was considered signifi cant. 
 Docking studies 
 The ligands were drawn using ChemBioDraw Ultra 12.0 and 
the 2D structures converted into 3D structures using ChemBio3D 
Ultra 12.0 (1986–2010 CambridgeSoft). The docking studies were 
performed using GOLD ( 34, 35 ), which uses a genetic algorithm 
to predict binding modes for small molecules in a protein bind-
ing site. The crystal structures for human and guinea pig 11  -
HSD1 were downloaded from the Protein Data Bank (PDB, www.
pdb.org) ( 36 ). PDB-entry 2BEL, chain A ( 37 ), was chosen for hu-
man protein, and 3LZ6, chain A ( 38 ), for guinea-pig protein. For 
human 11  -HSD1, the binding site was defi ned as an 8 Å sphere, 
centered with hydroxyl-oxygen of Ser170 (x: 3.84, y: 22.49, z: 
13.34). For the guinea-pig protein, the binding site was defi ned as 
an 8 Å sphere, centered by hydroxyl-oxygen of Tyr158 (x: 13.21, y: 
22.34, z: 45.45). For both enzymes, GoldScore was used as a scor-
ing function, and the program was set to defi ne the atom types for 
proteins and ligands automatically. The proteins were kept rigid 
and ligands fl exible during the docking run. To give the steroidal 
ligands more fl exibility, the program was set to fl ip ring corners 
while searching possible binding orientations for the ligands. For 
each ligand, a maximum of ten binding orientations were gener-
ated, but in case the three best-ranked solutions were within 
RMSD of 1 Å of each other, the program was allowed to terminate 
the run earlier. Using these settings, the program successfully re-
produced the binding orientations of the co-crystallized ligands 
carbenoxolone (2bel) and N-adamantan-2-yl-1-ethyl-D-prolin-
amide (3lz6), thus validating the docking settings. 
 RESULTS 
 Comparison of the oxidoreduction of 7-oxoLCA by 
11  -HSD1 from six species 
 We previously showed that human 11  -HSD1 preferen-
tially converts 7-oxoLCA to CDCA ( 26 ). Evidence from 
studies using rat liver microsomes indicated the formation 
of both CDCA and UDCA from 7-oxoLCA. In the present 
study, we investigated whether these observations are due 
to species-specifi c differences in the stereoselective prod-
uct formation by 11  -HSD1 or whether additional enzymes 
might be involved in the carbonyl reduction of 7-oxoLCA 
in rats and mice. Recombinant 11  -HSD1 from six species 
were expressed in HEK-293 cells, and the carbonyl reduc-
tion of 7-oxoLCA was determined by incubation of lysates 
at high total protein concentration with 1 µM of 7-oxoLCA 
 TABLE 1. Comparison of the oxidoreduction of 7-oxoLCA and cortisone by recombinant 
11  -HSD1 from six species 
Species
Oxidoreduction of 7-oxoLCA Oxidoreduction of Cortisone
 K m [µM] V max [nmol × h 
  1 × mg   1 ] Activity at 4 µM [nmol × h   1 × mg   1 ]
Canine 2.0 ± 0.4 52 ± 5 22 ± 5
Guinea-pig — — 22 ± 4
Hamster 4.2 ± 0.7 107 ± 11 27 ± 7
Human 1.2 ± 0.3 26 ± 2 16 ± 1
Mouse 2.0 ± 0.3 24 ± 2 10 ± 2
Rat 5.0 ± 0.5 86 ± 6 29 ± 8
The results are mean ± SD (n = 3).
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cytochrome c reductase activity in microsomes from livers 
of wild-type and liver-specifi c 11  -HSD1-defi cient mice 
and found no differences between the two preparations, 
indicating that the preparations were qualitatively compa-
rable (data not shown). 
 Comparison of circulating concentrations of 7-oxoLCA 
and its conjugates in serum from various species 
 Because 7-oxoLCA oxidoreductase activity was absent in 
guinea-pig liver microsomes and in lysates of HEK-293 
cells expressing recombinant guinea-pig 11  -HSD1, but it 
was present in all other species tested, we hypothesized 
that 7-oxoLCA and its conjugated metabolites accumu-
late in the serum of guinea-pigs but not in the other spe-
cies. Therefore, we determined the concentrations of 
7-oxoLCA, 7-oxoLC-Tau, and 7-oxoLC-Gly in the serum 
of various species, including guinea-pig (Dunkin-Hartley), 
there was almost no end-product inhibition of the reduc-
tion of 7-oxoLCA, and this bile acid was almost completely 
reduced by 11  -HSD1 ( Fig. 1A ). 11  -HSD1 dehydroge-
nase activity of all species, except guinea-pig, was most po-
tently inhibited by CDCA, with weaker effects by 7-oxoLCA 
and UDCA. 
 Relative contribution of 11  -HSD1 to the 
oxidoreduction of 7-oxoLCA 
 To clarify whether the oxidoreduction of 7-oxoLCA is 
mainly catalyzed by 11  -HSD1 or whether other enzymes 
are involved, we performed experiments with microsomes 
prepared from livers of wild-type and liver-specifi c 11  -
HSD1-knockout mice ( 33 ). To distinguish between NADPH-
dependent enzymes that are oriented to the cytosol, including 
cytochrome P450 enzymes, aldoketoreductases, and short-
chain dehydrogenase/reductase enzymes, and enzymes 
that are facing the endoplasmic reticulum (ER) lumen, 
such as 11  -HSD1, we compared activities in the presence 
of NADPH (for cytoplasmic enzymes) or G6P (for lumi-
nal enzymes). In the ER lumen, NADPH is regenerated 
by hexose-6-phosphate dehydrogenase (H6PDH), which 
is primarily dependent on G6P under physiological condi-
tions ( 39 ). Thus, intact liver microsomes, where the lumi-
nal compartment is protected by the ER membrane, 
contain an endogenous NADPH-regenerating system ( 40 ). 
After 60 min of incubation of liver microsomes from wild-
type mice with G6P, approximately 60% of initially sup-
plied 7-oxoLCA was converted to about two times more 
CDCA than UDCA ( Fig. 2 ).  The reaction was almost com-
pletely inhibited by the selective 11  -HSD1 inhibitor 
T0504 (also known as Merck-544) ( 41 ). When NADPH was 
added to the reaction mixture, we detected only traces of 
CDCA and UDCA, which were abolished by T0504, sug-
gesting that this activity was due to a small fraction of 
microsomes with inverted orientation. Importantly, in ex-
periments using liver microsomes from liver-specifi c 11  -
HSD1-knockout mice, no conversion of 7-oxoLCA could 
be detected, regardless of whether G6P or NADPH was 
supplied to the reaction mixture. As control, we measured 
 TABLE 2. Impact of bile acids on the interconversion of glucocorticoids by 11  -HSD1 from six species 
11  -HSD1 Species Reductase Activity IC 50 (µM) Dehydrogenase Activity IC 50 (µM)
Human 7-oxoLCA 1.1 ± 0.3 2.8 ± 0.8
UDCA 6.9 ± 1.2 2.3 ± 1.0
CDCA 4.1 ± 0.6 0.3 ± 0.1
Rat 7-oxoLCA 2.4 ± 0.9 11 ± 3
UDCA 13 ± 3 7 ± 3
CDCA 0.7 ± 0.1 0.7 ± 0.3
Mouse 7-oxoLCA 3.5 ± 0.6 12 ± 3
UDCA 32 ± 9 18 ± 3
CDCA 2.3 ± 0.4 1.6 ± 0.1
Hamster 7-oxoLCA 2.3 ± 0.9 29 ± 7
UDCA 21 ± 8 13 ± 4
CDCA 44 ± 14 5 ± 1
Canine 7-oxoLCA 0.9 ± 0.2 16 ± 3
UDCA 26 ± 5 18 ± 3
CDCA 1 ± 0.1 0.9 ± 0.2
Guinea pig 7-oxoLCA 15 ± 4 11 ± 20
UDCA 55 ± 15 39 ± 18
CDCA 22 ± 4 12 ± 2
The results are mean ± SD (n = 3).
 Fig.  2. Microsomes from livers of wild-type or liver-specifi c 11  -
HSD1 knockout (LKO) mice were incubated for 60 min with 
7-oxoLCA (1 µM), hexose-6-phosphate (1 mM G6P) or NAPDH 
(1 mM), and 11  -HSD1 inhibitor T0504 (5 µM) as indicated. 
7-oxoLCA is presented by white bars; CDCA and UDCA are pre-
sented by black and hatched bars, respectively. Data (n = 3) repre-
sent mean ± SD. Reactions were terminated with acetonitrile, and 
then extracted and measured by LC-MS/MS. 
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extended these fi ndings by comparing 11  -HSD1 from six 
species and observed remarkable species-specifi c differ-
ences. The catalytic activities of hamster and canine 11  -
HSD1 resembled those of the human enzyme. These two 
species preferentially reduced 7-oxoLCA to CDCA, sug-
gesting that they are suitable animal models to study po-
tential physiological and toxicological consequences of 
7-oxoLCA accumulation due to 11  -HSD1 defi ciency. In 
contrast, rat and mouse 11  -HSD1 were not stereoselective 
and produced substantial amounts of both 7  - and 7  -
hydroxylated forms. Interestingly, for the substrate 7-oxoc-
holesterol, the human, rat, and mouse enzymes generated 
7  -hydroxycholesterol exclusively, whereas the hamster en-
zyme was not stereoselective and formed both 7  - and 7  -
hydroxycholesterol ( 23 ). 
 Importantly, recombinant guinea-pig 11  -HSD1 and 
guinea-pig liver microsomes were unable to reduce 7-oxoLCA, 
providing an explanation for the very high levels of 7-oxoLCA 
and 7-oxoLC-Gly in the circulation of guinea-pigs compared 
with the other species investigated ( Table 3 ). Our fi ndings 
are in line with an earlier study suggesting that 7-oxoLCA is 
a primary bile acid in this species, accounting for 30% of the 
total bile acids contained in bile ( 42 ). Moreover, the high 
IC 50 values of 7-oxoLCA, CDCA, and UDCA for 11  -HSD1-
dependent cortisone reduction ( Table 2 ) suggest that the 
binding of these bile acids is not optimally stabilized in the 
substrate pocket of the guinea-pig enzyme. 
 The comparison of the superimposed 3D structures of 
human and guinea-pig 11  -HSD1 alone did not explain 
the species differences in 7-oxoLCA metabolism (see sup-
plementary Fig. I for alignment data). Therefore, 7-ox-
oLCA and cortisone were docked to human and guinea-pig 
11  -HSD1. In the reduction reaction, the hydrogen atoms 
are transferred to the ligand from the catalytic amino acid 
Tyr and the cofactor NADPH ( 43, 44 ). Therefore, the li-
gand needs to be oriented such that the carbonyl group is 
located in the vicinity of the catalytic Tyr and the cofactor. 
This is the case for cortisone, which binds similarly in 
human and guinea-pig 11  -HSD1 ( Fig. 3A , B ).  However, 
7-oxoLCA has different binding orientations in human 
and guinea-pig 11  -HSD1. In the human enzyme, as re-
ported earlier ( 26 ), 7-oxoLCA binds in an inverted orien-
tation with its A-ring aligning with the D-ring of cortisone 
and with the carbonyl group in position 7 in close proxim-
ity to the catalytic center, like the carbonyl group in posi-
tion 11 of cortisone ( Fig. 3C ). In contrast, a fl ipped binding 
mode of 7-oxoLCA is predicted for the guinea-pig enzyme, 
where the carbonyl group points away from the catalytic 
amino acids ( Fig. 3D ). This fl ipped binding orientation 
may be explained by steric reasons: 7-oxoLCA fi ts to the bind-
ing pocket, but because of the bulky side-chain in position 
human, mouse (balb/c and C57bL/6), rat (Han Wistar 
and Sprague-Dawley), canine ( Canis familiaris , beagle bred), 
and hamster (golden Syrian). We observed very high levels 
of 7-oxoLCA and its glycine conjugate in guinea-pig serum 
( Table 3 ).  In contrast, in all other species that were in-
vestigated and that express 7-oxoLCA oxidoreductase ac-
tivity, the circulating levels of 7-oxoLCA and its conjugates 
were very low. Taurine conjugation plays a minor role in 
guinea-pigs, and 7-oxoLC-Tau levels were negligible in this 
species. 
 Impact of 11  -HSD1 disruption on circulating levels of 
7-oxoLCA and its conjugates in mice 
 We hypothesized that 11  -HSD1 defi ciency and, there-
fore, the inability to reduce 7-oxoLCA, leads to elevated 
circulating levels of 7-oxoLCA and its conjugated metabo-
lites. To test this hypothesis, we measured the concentra-
tions of 7-oxoLCA and its taurine and glycine conjugates 
in serum and in liver tissue of liver-specifi c and global 11  -
HSD1-defi cient mice ( Table 4 ).  The glycine conjugation 
plays a minor role in mice, in contrast to guinea-pigs, and 
concentrations of 7-oxoLC-Gly were very low in serum and 
liver tissue of liver-specifi c 11  -HSD1-knockout and wild-
type mice. In liver tissue of liver-specifi c knockout and 
global knockout mice, 7-oxoLCA levels were approximately 
two times higher, although the differences did not reach 
statistical signifi cance. In contrast, intrahepatic 7-oxoLC-
Tau was 7-fold and 4-fold higher in liver-specifi c 11  -HSD1-
defi cient mice and in global 11  -HSD1-defi cient mice 
compared with wild-type controls. As expected, 7-oxoLC-Tau 
levels were generally higher than 7-oxoLCA levels in liver 
tissue. Circulating levels of 7-oxoLC-Tau were somewhat 
higher than free 7-oxoLCA levels. Importantly, 7-oxoLCA 
concentrations signifi cantly increased (6-fold) in serum of 
liver-specifi c 11  -HSD1-defi cient mice and further increased 
(24-fold) in global-knockout mice. Circulating 7-oxoLC-
Tau levels were 40-fold higher in liver-specifi c 11  -HSD1-
knockout mice compared with wild-type mice, and they were 
even somewhat lower in serum of global-knockout mice 
(20-fold higher than wild-type mice). 
 DISCUSSION 
 Recently, we reported that 7-oxoLCA and its taurine 
and glycine conjugates are substrates of human 11  -HSD1 
and that they are effi ciently converted to the 7  -hydroxylated 
CDCA and, to a lesser extent, to the 7  -hydroxylated 
UDCA ( 26 ). At physiological pH, 11  -HSD1 exclusively 
catalyzed the reduction of 7-oxoLCA, and neither CDCA 
nor UDCA served as substrate. In the present study, we 
 TABLE 3. Concentrations of 7-oxoLCA and its conjugates in the serum from several species 
Dog Guinea-pig Hamster Human Mouse (Balb/c) Mouse (C57BL/6) Rat (Han Wistar) Rat (Sprague -Dawley)
7-oxoLCA 41 ± 83 13593 ± 5482 11 ± 9 3 ± 1 20 ± 12  6 ± 4  4 ± 5 22 ± 28
7-oxoLC-Tau 9 ± 11 3 ± 2 3 ± 1 1 ± 0.1 8 ± 2 32 ± 14 2 ± 0.2 4 ± 1
7-oxoLC-Gly 1 ± 0.2 5481 ± 3557 1 ± 1 1 ± 0.1 5 ± 3 ND ND 1 ± 2
The results are expressed in nM as mean ± SD (n = 8). Underlined values represent below lower limit of quantifi cation. ND, not detected.
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 Analysis of the 7-oxoLCA levels in liver tissue indicated 
a trend to increase (approximately 2-fold) in liver-specifi c 
and global 11  -HSD1-knockout mice. Serum levels, how-
ever, were signifi cantly increased 6-fold and 24-fold. Thus, 
serum 7-oxoLCA is a better biomarker for 11  -HSD1 defi -
ciency than is intrahepatic 7-oxoLCA. Importantly, a sig-
nifi cant increase in both hepatic and circulating levels of 
7-oxoLC-Tau was obtained with a more pronounced in-
crease in serum (40-fold and 20-fold) compared with liver 
tissue (7-fold and 4-fold). The reason why 7-oxoLC-Tau is 
higher in liver-specifi c compared with global knockout 
mice remains unclear but may be due to compensatory 
mechanisms or differences in gut microbiota. In liver-
specifi c and global 11  -HSD1-knockout mice, unlike in 
guinea-pigs, taurine conjugation of 7-oxoLCA is the main 
route of its elimination in mice and glycine conjugation 
can be neglected. Based on these findings, we propose 
that 7-oxoLCA and 7-oxoLC-Tau, as well as the sum of 
these two bile acids, may represent suitable biomarkers of 
11  -HSD1 defi ciency. 
17 of the steroid backbone, the binding mode is unfavorable 
for the reduction reaction. However, when binding to the 
enzyme, 7-oxoLCA prevents other ligands from binding, ex-
plaining its action as a weak competitive inhibitor. These 
docking results support our biological fi ndings that cortisone 
is metabolized by both human and guinea-pig 11  -HSD1 but 
that 7-oxoLCA is not reduced by the guinea-pig enzyme. 
 Our data clearly show that guinea-pig 11  -HSD1 is able 
to reduce cortisone. Thus, glucocorticoid activation is simi-
larly catalyzed in guinea-pigs and the other species investi-
gated. 11  -HSD1 is a highly effi cient enzyme, and upon 
pharmacological application, cortisone and prednisone are 
almost completely converted to cortisol and prednisolone 
in the liver. Thus, the lack of the reduction of 7-oxoLCA 
(produced by intestinal microorganisms) by 11  -HSD1 in 
the liver may be responsible, at least in part, for the high 
circulating levels in this species. Because 11  -HSD1 seems 
to be the only enzyme responsible for the reduction of 
7-oxoLCA, we hypothesized that this bile acid and its conju-
gates would accumulate in 11  -HSD1-defi cient mice. 
 TABLE 4. Circulating and intrahepatic concentrations of 7-oxoLCA and its conjugates in 
mouse models of 11  -HSD1 defi ciency 
Circulation (nM) Intrahepatic (fmol/mg)
WT LKO KO WT LKO KO
7-oxoLCA 15 ± 11 91 ± 152** 360 ± 529*** 15 ± 10 33 ± 34 27 ± 21
7-oxoLC-Tau 22 ± 19 875 ± 1210* 407 ± 392*** 200 ± 188 1458 ± 1705*** 874 ± 945***
7-oxoLC-Gly 14 ± 14 4 ± 6 18 ± 16 8 ± 8 10 ± 9 2 ± 1
The results are expressed in nM as mean ± SD. Wild-type (WT) (n = 24), liver-specifi c 11  -HSD1-defi cient mice 
(LKO) (n = 16) and global 11  -HSD1-defi cient mice (KO) (n = 8). Data represent mean ± SD. * P   0.05, 
** P   0.01, *** P   0.001.
  
 Fig.  3. The predicted binding orientations of cortisone in (A) human and (B) guinea-pig and 7-oxoLCA in (C) human and (D) guinea-
pig in the 11  -HSD binding sites. The catalytic triad Ser-Tyr-Lys is highlighted in ball-and-stick style, and the cofactor NADPH, in bold 
sticks. The ligands are represented in gray. 
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other investigators ( 53 ). Similar to humans and guinea-
pigs, glycine conjugation seems to prevail in hamsters 
( 54 ), whereas in rodents and canines, taurine conjugation 
prevails and only minor amounts of glycine conjugated 
bile acids were detected, in line with observations by other 
investigators ( 52, 55 ). Nevertheless, the applicability of 
7-oxoLCA and its conjugates as potential biomarkers of 
11  -HSD1 defi ciency and inhibition requires further in-
vestigation in vivo using specifi c 11  -HSD1 inhibitors or in 
clinical situations, such as patients suffering from corti-
sone reductase defi ciency. 
 CONCLUSIONS 
 Our results provide further evidence for an exclusive 
role of 11  -HSD1 in the reduction of 7-oxoLCA, which is 
generated by intestinal microorganisms, reaches the liver 
after entering the enterohepatic cycle, and is rapidly me-
tabolized to CDCA and UDCA. Unlike glucocorticoids, the 
substrate 7-oxoLCA and particularly its taurine conjugate 
were markedly elevated in the serum of liver-specifi c 11  -
HSD1-defi cient mice. Because 7-oxo and 7-oxoLC-Tau 
are not under the control of the HPA axis and they do not 
act through classical bile acid receptors, their concentra-
tions do not seem to be regulated by feedback mechanisms, 
and they may be used as biomarkers to detect impaired 
11  -HSD1 activity in clinically relevant situations. Future 
studies are needed to validate the use of these bile acids as 
biomarkers for reduced 11  -HSD1 activity, for example, in 
animal models and patients treated with 11  -HSD1 inhibi-
tors and in patients with cortisone reductase defi ciency.  
 The authors thank Dr. Alan F. Hofmann (University of 
California, San Diego) for providing 7-oxoLC-Tau and 7-oxoLC-
Gly, and Drs. François Pognan, Armin Wolf, and Heiko Schadt, 
Novartis AG, Basel, for critical comments. 
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